Study
This large Austrian insurance-based study found that monoclonal antibodies targeting CGRP significantly reduced migraine frequency and health care ...
In plain language
This large Austrian insurance-based study found that monoclonal antibodies targeting CGRP significantly reduced migraine frequency and health care use. Benefits were consistent across age groups, including adults over 60.
Use the full description to understand the study design, methods, and the limits of the findings.
A nationwide analysis in Austria found that patients treated with CGRP monoclonal antibodies experienced fewer migraine days and hospitalizations, confirming the safety and effectiveness of this therapy for migraine prevention.
Open the original publication for the complete methods, outcomes, and source material.
Published December 2025
Opens at the publisher · external site · may require institutional access
The study provides useful insights into the use of monoclonal antibodies for migraine prevention in older adults, but its retrospective design and potential biases limit the strength of its conclusions. It is relevant to seniors but should be interpreted with caution due to methodological limitations.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 5.0/10 | |
| Bias & Methods | 4.0/10 | |
| Statistical Integrity | 6.0/10 | |
| Transparency | 7.0/10 | |
| Conflict of Interest Disclosure | 8.0/10 | |
| Replication / External Validation | 5.0/10 | |
| Relevance to Seniors | 7.0/10 | |
| Journal Quality | 8.0/10 |
Future studies should aim for prospective designs with clear bias control methods to strengthen evidence quality.
Build a personalized plan using research-backed studies, conditions, and treatments.